Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03353688 · ClinicalTrials.gov registry record · NA
Biomarkers to Guide Directional DBS for Parkinson's Disease
A NA study, sponsored by University of Alabama at Birmingham.
- Completed
- Registry status
- NA
- Development phase
- 31
- Enrollment target
NCT03353688 is a NA study that has completed, run by University of Alabama at Birmingham. The registered enrollment target is 31 participants.
The verdict
NCT03353688, a NA study, has completed, sponsored by University of Alabama at Birmingham.
- COMPLETED
- Registry status
- NA
- Development phase
- 31 participants
- Enrollment target
Study Summary
The purpose of this study is to investigate the clinical efficacy of directional DBS electrode technology and whether electrophysiology biomarkers can predict effective contact segments for chronic therapy.
Interventions
- DEVICE Boston Scientific Vercise PC IPG with directional DBS lead
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2017-11-03 |
| Est. Completion | 2024-07-31 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03353688
The ClinicalTrials.gov registry entry for NCT03353688 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 31 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Alabama at Birmingham, which has 1,160 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Boston Scientific Vercise PC IPG with directional DBS lead is the first listed.
NCT03353688 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03353688 about?
NCT03353688 is a clinical study titled "Biomarkers to Guide Directional DBS for Parkinson's Disease". The purpose of this study is to investigate the clinical efficacy of directional DBS electrode technology and whether electrophysiology biomarkers can predict effective contact segments for chronic therapy.
What is the current status of trial NCT03353688?
This trial is currently completed. It is a NA study. The enrollment target is 31 participants. The study started on 2017-11-03. Estimated completion is 2024-07-31.
What interventions are being tested in trial NCT03353688?
The interventions under investigation include: Boston Scientific Vercise PC IPG with directional DBS lead (DEVICE).
Who is sponsoring clinical trial NCT03353688?
This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.